LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
20. Mai 2021 06:30 ET
|
LAVA Therapeutics BV
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both...
LAVA Therapeutics将出席2021年UBS全球医疗保健虚拟会议
18. Mai 2021 06:30 ET
|
LAVA Therapeutics BV
荷兰乌得勒支和美国费城, May 18, 2021 (GLOBE NEWSWIRE) -- 专注于运用其双特异性γ-δ T细胞结合物专业知识来改变癌症疗法的生物技术公司LAVA Therapeutics N.V.（纳斯达克代码：LVTX）今天宣布其首席执行官Stephen Hurly将出席东部时间2021年5月26日星期三下午1点举行的2021年UBS全球医疗保健 虚拟会议。 ...
LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
18. Mai 2021 06:30 ET
|
LAVA Therapeutics BV
UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta...
LAVA Therapeutics任命Karen J. Wilson为董事会成员
02. April 2021 03:24 ET
|
LAVA Therapeutics BV
荷兰乌得勒支和美国费城, April 02, 2021 (GLOBE NEWSWIRE) -- 专注于运用其双特异性γ-δ T细胞结合物（bsTCEs）专业知识来改变癌症疗法的生物技术公司LAVA Therapeutics N.V.（Nasdaq：LVTX）今天宣布任命Karen Wilson担任董事会成员兼审计委员会主席。Wilson女士将带来生命科学行业30多年的财务和领导经验。 ...
LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors
01. April 2021 07:54 ET
|
LAVA Therapeutics BV
UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific...
LAVA Therapeutics宣布首次公开发行股价
25. März 2021 03:12 ET
|
LAVA Therapeutics BV
荷兰乌得勒支和美国费城, March 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V.（纳斯达克股票代码：LVTX），一家专注于使用其在双特异性gamma-delta T细胞衔接蛋白抗体构建体方面的专业知识来转变癌症疗法的生物科技公司，今天宣布其首次公开发行的6,7000,000股普通股定价为每股15美元。此外，LAVA...
LAVA Therapeutics Announces Pricing of Initial Public Offering
24. März 2021 20:55 ET
|
LAVA Therapeutics BV
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific...